Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants 2 months of age (54-75 days of age) on date of first vaccination~* Healthy assessed from medical history and physical examination~* Parent(s)/guardian(s) have been properly informed about the trial and signed informed consent form~* Parent(s)/guardian(s)granted access to the infant's trial related medical records~* Parent(s)/guardian(s)are likely to comply with trial procedures~Exclusion Criteria:~* Vaccinated with any polio vaccine other than the trial vaccines, prior to inclusion or planned during the trial~* OPV vaccination or known exposure to poliovirus (wild or vaccine-derived) in household (living together) within 3 months prior to inclusion or planned during the trial~* Low birth weight (\< 2,500 g)~* Known or suspected immunodeficiency (e.g. leukaemia, lymphoma) or family history of congenital or hereditary immunodeficiency. HIV infection is not an exclusion criteria~* Severe uncontrolled chronic (e.g. neurologic, pulmonary, gastrointestinal, hepatic, renal or endocrine) disease~* Known or suspected allergy to vaccine constituents (e.g. hypersensitivity to formaldehyde, aluminium or 2-phenoxyethanol)~* Uncontrolled coagulopathy or blood disorder contraindicating intramuscular injections or blood sampling~* Treatment with a product which is likely to modify the immune response (e.g. systemic corticosteroids, blood products and immunoglobulins) prior to inclusion or planned during the trial period~* Participating in another clinical trial~* Not suitable for inclusion in the opinion of the investigator

- Gender: ALL
- Minimum Age: 54 Days
- Maximum Age: 75 Days
- Healthy Volunteers: t

Study Arms:
- IPV-Al SSI (Type: EXPERIMENTAL): IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. Each subject randomised to this group will receive a total of three primary injections - one at 2 months, 4 months and 6 months of age.
- IPV SSI (Type: ACTIVE_COMPARATOR): IPV SSI contains the full dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. Each subject randomised to this group will receive a total of three primary injections - one at 2 months, 4 months and 6 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).